| Sam Lovick is a Principal practicing across corporate strategy, health and biotechnology, electricity, water and trade practices fields. Sam has recently completed five years as the Chief Economist of CSL Limited, where he worked on a wide range of strategic and public policy issues. He has wide knowledge of health, pharmaceutical and biotechnology in Australia and in major overseas markets. Prior to joining CSL, Sam worked for 17 years as an economic consultant working in the UK, US and Australia. He worked in the electricity industry, water, airports, health, the plasma fraction and pharmaceutical industries, telecommunications and the economics of performance measurement.
Skills and capabilities:
Corporate strategy Economics of health, pharmaceuticals and biotechnology Economic impact and cost benefit analysis Competition policy and trade practices Public policy advice Corporate finance
Project experience: Telecommunications for a variety of clients including Telstra, Telecom NZ, and Oftel covering performance measurement, market design, regulation and trade practices issues and numbering; Price regulation experience for Telstra, the Ontario Energy Board, the Argentine Economic Regulator and for multiple power companies on the US, Canada, UK and Australia; Expert testimony in US regulatory hearings and assistance in preparation of expert testimony in telecommunications, credit cards, gas markets and transportation; Power sector market design and restructuring in UK, Australia, California, Texas, Ontario, Alberta, South Africa and New Zealand; Power sector market simulation software for UK, Australia, Colombia, California, Texas, New England, the US Pacific North West, New Zealand; Power sector mergers and acquisitions in Australia, US, Argentina, Colombia, Singapore; Analysis of market power and competition issues in power markets in California, NSW, South Australia, Texas and New Zealand; Gas analysis and advice in a number of markets including advice to Shell and BHP; Water regulatory and restructuring advice in the UK, Australia and the US; and Pharmaceutical, biotechnology and health advice to a variety of government and private sector clients (including CSL prior to 2004).
|
